New Research on Oncology - Endometrial Cancer Yields Promising Results

Strategic Insights -

New research at the University of Kentucky has made significant breakthroughs in the treatment of endometrial cancer, a type of cancer that affects the lining of the uterus. According to the study, researchers have developed a new drug delivery system (DDS) that can encapsulate a chemotherapy drug called paclitaxel, allowing for targeted and localized delivery to specific tissues. This DDS, made from a biocompatible polymer called polycaprolactone (PCL), has shown to increase circulation time and therapeutic effects while reducing systemic side effects.

Key Takeaways:

  • The new DDS uses a polycaprolactone (PCL) particle loaded with paclitaxel, a chemotherapy drug.
  • The DDS demonstrated sustained release of paclitaxel for at least 28 days.
  • The antiproliferative activity of paclitaxel was enhanced in cells at lower concentrations compared to the free drug.
  • The study indicated that PCL is a potential polymer for further development of DDS for cancer therapeutics.
  • The researchers used confocal microscopy to confirm intracellular localization of the dye in endometrial cancer cell lines.
  • The study found that approximately 22% of the cargo was released in the first 48 hours.
  • The DDS was tested in Ishikawa and KLE endometrial cancer cell lines.
  • The study's authors include Brittany E. Givens, Claire E. Rowlands, and Megan Dwyer.

Statistics:

  • 22% of the cargo was released in the first 48 hours.
  • The DDS demonstrated sustained release of paclitaxel for at least 28 days.
  • The study was published in the Journal of Biomedical Materials Research Part A, volume 113, issue 8.
  • The study's authors cited a 28-day sustained release of paclitaxel.
  • TheDDS was tested in at least two endometrial cancer cell lines.

Sources:

  • "In Vitro Assessment of a Paclitaxel-poly(Caprolactone) Drug Delivery System In Endometrial Cancer" (Journal of Biomedical Materials Research Part A, 2025;113(8))
  • University of Kentucky, College of Engineering, Dept. of Chemical and Materials Engineering
  • OBGYN & Reproduction Week, October 20, 2025, p 720
  • NewsRx, Reports Outline Endometrial Cancer Study Results from University of Kentucky [In Vitro Assessment of a Paclitaxel-poly(Caprolactone) Drug Delivery System In Endometrial Cancer].